210484-86-9

Upstream product

• 2675-79-8 1-bromo-3,4,5-trimethoxybenzene 
• 210484-85-8 (7S,8R,11S)-8-Allyl-11-benzoyl-9-oxo-2-oxa-10-aza-bicyclo[11.2.2]heptadeca-1⁽¹⁶⁾,13⁽¹⁷⁾,14-triene-7-carboxylic acid tert-butyl ester 
• 210484-15-4 2-allyl-3-[4-(tert-butyl-dimethyl-silanyloxy)-butyl]-succinic acid 4-tert-butyl ester 
• 393525-46-7 2-allyl-3-[4-(tert-butyl-dimethyl-silanyloxy)-butyl]-succinic acid 4-tert-butyl ester 
• 179533-97-2 (R)-2-(2-(tert-butoxy)-2-oxoethyl)pent-4-enoic acid 

Downstream Products

• 210484-01-8 (7S,8R,11S)-11-Benzoyl-9-oxo-8-[3-(3,4,5-trimethoxy-phenyl)-propyl]-2-oxa-10-aza-bicyclo[11.2.2]heptadeca-1⁽¹⁶⁾,13⁽¹⁷⁾,14-triene-7-carboxylic acid 

Relevant academic research and scientific papers

Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme

Modification of the P1′ substituent of macrocyclic matrix metalloproteinase (MMP) inhibitors provided compounds that are selective for inhibition of tumor necrosis factor-α converting enzyme (TACE) over MMP-1 and MMP-2. Several analogues potent